TransMedics Group, Inc. (TMDX) Net Income
The trailing-twelve-month (TTM) net income for TransMedics Group, Inc. (TMDX) is $171.92 Million with a year-over-year change of +251.23%. Net income represents the company's bottom line profit after all expenses, taxes, and interest.
TMDX Annual Net Income
Net Income (TTM)
$171.92M
$171.92 Million
Year-over-Year Change
+251.23%
vs. $48.95M a year ago (TTM)
Net Income CAGR
+251.23%
1 Year compound annual growth rate
Net Income CAGR (Compound Annual Growth Rate)
1 Year
+251.23%
3 Year
N/A
5 Year
N/A
10 Year
N/A
15 Year
N/A
20 Year
N/A
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
Annual Net Income History
| Year | Net Income | YoY Change | % Change |
|---|---|---|---|
| 2025 | $190.29M | +$154.83M | +436.58% |
| 2024 | $35.46M | +$60.49M | — |
| 2023 | ($25.03M) | +$11.20M | — |
| 2022 | ($36.23M) | +$7.98M | — |
| 2021 | ($44.22M) | ($15.47M) | — |
| 2020 | ($28.75M) | +$4.80M | — |
| 2019 | ($33.55M) | ($9.79M) | — |
| 2018 | ($23.76M) | ($2.93M) | — |
| 2017 | ($20.82M) | +$3.24M | — |
Net Income Growth Summary
TTM Growth
+251.23%
3-Year Avg Growth
+556.66%
5-Year Avg Growth
+581.02%
About TransMedics Group, Inc.
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Waleed H. Hassanein